Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PBRM1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PBRM1 mutation	Bladder Cancer	PBRM1 mutation	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PBRM1 mutation	Bladder Cancer	PBRM1 mutation	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation	Non Small Cell Lung Cancer	PBRM1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation	Lung Adenocarcinoma	PBRM1 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PBRM1 mutation	Cholangiocarcinoma	PBRM1 mutation	Cholangiocarcinoma	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3
PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
PBRM1 mutation	Biliary Tract Cancer	PBRM1 mutation	Biliary Tract Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
PBRM1 mutation	Chordoma	PBRM1 mutation	Chordoma	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D	tazemetostat Sensitive: D – Preclinical tazemetostat Sensitive : D
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	PRT1419 Sensitive: D – Preclinical PRT1419 Sensitive : D	PRT1419 Sensitive: D – Preclinical PRT1419 Sensitive : D